{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:49:29Z","timestamp":1761490169141,"version":"3.41.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003329","name":"MINECO","doi-asserted-by":"publisher","award":["SAF2015-68580-C2"],"award-info":[{"award-number":["SAF2015-68580-C2"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Programa de Biomedicina, Comunidad de Madrid","award":["S2011\/BMD-2308"],"award-info":[{"award-number":["S2011\/BMD-2308"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ejmech.2017.01.002","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T20:44:40Z","timestamp":1483649080000},"page":"398-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking"],"prefix":"10.1016","volume":"127","author":[{"given":"Giulio","family":"Ragusa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"G\u00f3mez-Ca\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Rodr\u00edguez-Cueto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda R.","family":"Pazos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Battistina","family":"Asproni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Cichero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Fossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard A.","family":"Pinna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Jagerovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Murineddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.01.002_bib1","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, structure, and partial synthesis of an active constituent of hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2017.01.002_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.01.002_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.01.002_bib4","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2017.01.002_bib5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/372686a0","article-title":"Formation and inactivation of endogenous cannabinoid anandamide in central neurons","volume":"372","author":"Di Marzo","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.01.002_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","article-title":"Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors","volume":"50","author":"Mechoulam","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.01.002_bib7","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.2174\/092986710790980005","article-title":"Endocannabinoid binding to the cannabinoid receptors; what is known and what remains unknown","volume":"17","author":"Reggio","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib8","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/sj.ijo.0803272","article-title":"The pharmacology of cannabinoid receptors and their ligands: an overview","volume":"30","author":"Pertwee","year":"2006","journal-title":"Int. J. Obes."},{"issue":"3","key":"10.1016\/j.ejmech.2017.01.002_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1476-5381.2008.00048.x","article-title":"Emerging strategies for exploiting cannabinoid receptor agonists as medicines","volume":"156","author":"Pertwee","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.01.002_bib10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.pbb.2008.05.010","article-title":"Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures-a short review","volume":"90","author":"Sv\u00edzensk\u00e1","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"5","key":"10.1016\/j.ejmech.2017.01.002_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tips.2015.02.008","article-title":"Endocannabinoid signalling at the periphery: 50 years after THC","volume":"36","author":"Maccarrone","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2017.01.002_bib12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1476-5381.2011.01352.x","article-title":"The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications","volume":"163","author":"Kunos","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"25","key":"10.1016\/j.ejmech.2017.01.002_bib13","doi-asserted-by":"crossref","first-page":"20851","DOI":"10.1074\/jbc.M111.335273","article-title":"Cannabinoid receptors CB1 and CB2 form functional heteromers in brain","volume":"287","author":"Call\u00e9n","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2017.01.002_bib14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0022-3565(25)38122-X","article-title":"Cannabinoid structure-activity relationships: correlation of receptor binding and in\u00a0vivo activities","volume":"265","author":"Compton","year":"1993","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2017.01.002_bib15","doi-asserted-by":"crossref","unstructured":"A. Dhopeshwarkar, K. Mackie, CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?, Mol. Pharmacol.. 86 (4) (214) 430\u2013437.","DOI":"10.1124\/mol.114.094649"},{"key":"10.1016\/j.ejmech.2017.01.002_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1021\/acs.chemrev.5b00411","article-title":"Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB2 receptor agonists","volume":"116","author":"Tabrizi","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2017.01.002_bib17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/13543776.2016.1193157","article-title":"Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update","volume":"26","author":"Morales","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2017.01.002_bib18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ejmech.2015.06.057","article-title":"Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists","volume":"101","author":"Ragusa","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib19","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1021\/jm400070u","volume":"56","author":"Kotsikorou","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0968-0896(02)00319-X","article-title":"Tricyclic pyrazoles. I. Synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1 and CB2 cannabinoid receptors","volume":"11","author":"Mussinu","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib21","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1021\/jm060920d","article-title":"Tricyclicpyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide","volume":"49","author":"Murineddu","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874104501206010001","article-title":"Tricyclic Pyrazoles. Part 5. Novel 1,4-dihydroindeno[1,2-c]pyrazole CB2 ligands using molecular hybridization based on scaffold hopping","volume":"6","author":"Murineddu","year":"2012","journal-title":"Open Med. Chem. J."},{"key":"10.1016\/j.ejmech.2017.01.002_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejmech.2014.05.055","article-title":"Tricyclicpyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands","volume":"82","author":"Pinna","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ejmech.2014.08.042","article-title":"Tricyclic pyrazoles Part 7. Discovery of potent and selective dihydrothienocyclopentapyrazole derived CB2 ligands","volume":"85","author":"Pinna","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib25","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.3390\/molecules14093494","article-title":"Synthesis and cytotoxicity of novel hexahydrothieno-cycloheptapyridazinone derivatives","volume":"14","author":"Pau","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2017.01.002_bib26","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/cmdc.201500124","article-title":"Multitarget-directed tricyclic pyridazinones as G protein-coupled ligands and cholinesterase inhibitors","volume":"10","author":"Pau","year":"2015","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib27","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/S0957-4166(98)00243-2","article-title":"Reaction of per-O-acetylglucosyl isothiocyanate with carbon bases. A new method for the stereocontrolled synthesis of nucleosides and glucosylaminothiophenes","volume":"9","author":"Fuentes","year":"1998","journal-title":"Tetrahedron Asymmetry"},{"key":"10.1016\/j.ejmech.2017.01.002_bib28","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1021\/jm960124f","article-title":"Synyhesis, activity, and molecular modeling of a new series of trycyclic pyridazinones as selective aldose reductase inhibitors","volume":"39","author":"Costantino","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"issue":"25","key":"10.1016\/j.ejmech.2017.01.002_bib29","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.96.25.14228","article-title":"HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor","volume":"96","author":"Hanus","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.01.002_bib30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/156802611794480927","article-title":"In-Silico ADME models: a general assessment of their utility in drug discovery applications","volume":"11","author":"Gleeson","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0169-409X(02)00008-X","article-title":"Prediction of drug solubility from structure","volume":"54","author":"Jorgensen","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2017.01.002_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2001","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejmech.2017.01.002_bib33","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2009","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2017.01.002_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2017.01.002_bib35","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1039\/C5MD00333D","article-title":"Ligand-based homology modelling of the human CB2 receptor SR144528 antagonist binding site: a computational approach to explore the 1, 5-diaryl pyrazole scaffold","volume":"6","author":"Cichero","year":"2015","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.ejmech.2017.01.002_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2016.02.032","article-title":"Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists","volume":"113","author":"Tabrizi","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejmech.2016.02.005","article-title":"Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist\/inverse agonist properties","volume":"112","author":"Deiana","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2017.01.002_bib38","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/j.ejmech.2008.01.043","article-title":"Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant","volume":"43","author":"Menozzi","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib39","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1126\/science.1150577","article-title":"Accelerated technologies center for gene to 3D structure, GPCR network high-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor","volume":"318","author":"Cherezov","year":"2007","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ejmech.2017.01.002_bib40","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00894-008-0356-2","article-title":"Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis","volume":"14","author":"Cichero","year":"2008","journal-title":"J.\u00a0Mol. Model"},{"issue":"3","key":"10.1016\/j.ejmech.2017.01.002_bib41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/sj.bjp.0702351","article-title":"Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630","volume":"126","author":"Ross","year":"1999","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2017.01.002_bib42","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-3565(24)38760-9","article-title":"In\u00a0vitro and in\u00a0vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor","volume":"296","author":"Iwamura","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2017.01.002_bib43","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0022-3565(24)37266-0","article-title":"SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor","volume":"284","author":"Rinaldi-Carmona","year":"1998","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2017.01.002_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1124\/jpet.103.049924","article-title":"Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor","volume":"306","author":"Ruiu","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2017.01.002_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14728210902736568","article-title":"Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis","volume":"14","author":"Janero","year":"2009","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"3","key":"10.1016\/j.ejmech.2017.01.002_bib46","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1021\/jm00107a019","article-title":"Synthesis of 2-exo- and 2-endo-mecamylamine analogues. Structure-activity relationships for nicotinic antagonism in the central nervous system","volume":"34","author":"Suchocki","year":"1991","journal-title":"J.\u00a0Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2017.01.002_bib47","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1016\/j.ejmech.2011.07.023","article-title":"Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the agonist binding site of the human CB2 receptor","volume":"46","author":"Cichero","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0014-2999(00)00439-8","article-title":"Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor","volume":"28","author":"Gouldson","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2017.01.002_bib49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1021\/jm200421e","article-title":"Synthesis, biological evaluation, and docking studies of tetrahydrofuran- cyclopentanone- and cyclopentanol-based ligands acting at adrenergic \u03b11- and serotonine 5-HT1A receptors","volume":"55","author":"Prandi","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib50","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1039\/C5MD00490J","article-title":"A\u00a0homology modelling-driven study leading to the discovery of the first mouse trace amine-associated receptor 5 (TAAR5) antagonists","volume":"7","author":"Cichero","year":"2016","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.ejmech.2017.01.002_bib51","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1021\/jm0302647","article-title":"An aromatic microdomain at the cannabinoid CB1 receptor constitutes an agonist\/inverse agonist binding region","volume":"46","author":"McAllister","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.01.002_bib52","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1016\/j.bmc.2015.04.070","article-title":"e. Cichero, in silico evaluation of human small heat shock protein HSP27: homology modeling, mutation analyses and docking studies","volume":"23","author":"Fossa","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"112","key":"10.1016\/j.ejmech.2017.01.002_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2016.01.059","article-title":"Scouting new sigma receptor ligands: synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives","volume":"13","author":"Franchini","year":"2016","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417300028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417300028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T01:32:46Z","timestamp":1749864766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417300028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":53,"alternative-id":["S0223523417300028"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.01.002","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}